• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.肺炎链球菌编码DNA拓扑异构酶IV的parC和parE基因的克隆与特性分析:在氟喹诺酮耐药性中的作用
J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.
2
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构:氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
3
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.DNA 回旋酶和拓扑异构酶IV是环丙沙星作用于肺炎链球菌的双重靶点。
Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810.
4
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.拓扑异构酶IV和DNA促旋酶作为环丙沙星在肺炎链球菌中的作用靶点。
Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6. doi: 10.1128/AAC.40.10.2321.
5
ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.肺炎链球菌DNA拓扑异构酶IV的ParC亚基是氟喹诺酮类药物的主要作用靶点,并与DNA回旋酶A亚基协同形成耐药表型。
Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7. doi: 10.1128/AAC.40.10.2252.
6
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.新型氟喹诺酮类药物对肺炎链球菌临床分离株的活性,包括那些gyrA、parC和parE基因座发生突变的分离株。
Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329.
7
Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.吉米沙星强大的抗肺炎球菌活性与对回旋酶和拓扑异构酶IV的双重靶向作用、在体内对回旋酶的靶点偏好以及在体外增强可裂解复合物的稳定性有关。
Antimicrob Agents Chemother. 2000 Nov;44(11):3112-7. doi: 10.1128/AAC.44.11.3112-3117.2000.
8
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.拓扑异构酶IV中的喹诺酮耐药性突变:与flqA位点的关系以及金黄色葡萄球菌中拓扑异构酶IV是氟喹诺酮类药物的主要靶点而DNA回旋酶是次要靶点的遗传学证据。
Antimicrob Agents Chemother. 1996 Aug;40(8):1881-8. doi: 10.1128/AAC.40.8.1881.
9
Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.肺炎链球菌GyrA和ParC蛋白中的喹诺酮耐药性突变:基于酶分析、细胞内水平以及野生型和突变型蛋白表型对喹诺酮作用机制的深入了解
Antimicrob Agents Chemother. 2001 Nov;45(11):3140-7. doi: 10.1128/AAC.45.11.3140-3147.2001.
10
Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.人型支原体DNA促旋酶(gyrA)基因的克隆、核苷酸序列分析及体外筛选的曲伐沙星耐药突变株的特性研究
Antimicrob Agents Chemother. 2000 Oct;44(10):2719-27. doi: 10.1128/AAC.44.10.2719-2727.2000.

引用本文的文献

1
Structural basis of topoisomerase targeting by delafloxacin.达氟沙星作用于拓扑异构酶的结构基础
Nat Commun. 2025 Jul 1;16(1):5829. doi: 10.1038/s41467-025-60688-3.
2
Demographic fluctuations in bloodstream lineages configure the mobile gene pool and antimicrobial resistance.血流谱系中的人口统计学波动构成了移动基因库和抗菌素耐药性。
NPJ Antimicrob Resist. 2024;2(1):14. doi: 10.1038/s44259-024-00032-9. Epub 2024 May 7.
3
Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones.用新型7,8-桥连氟喹诺酮类药物探索肺炎链球菌拓扑异构酶IV-DNA切割复合物的活性位点。
Open Biol. 2016 Sep;6(9). doi: 10.1098/rsob.160157.
4
Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.结合疫苗时代前后美国耐抗生素肺炎链球菌的生物学和流行病学特征
Clin Microbiol Rev. 2016 Jul;29(3):525-52. doi: 10.1128/CMR.00058-15.
5
Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex.肺炎克雷伯菌拓扑异构酶IV喹诺酮稳定切割复合物的结构及其与相关肺炎链球菌复合物的比较。
Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):488-96. doi: 10.1107/S2059798316001212. Epub 2016 Mar 24.
6
Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport.“开放”夹钳型 II 拓扑异构酶-DNA 复合物的结构提供了 DNA 捕获和转运的机制。
Nucleic Acids Res. 2013 Nov;41(21):9911-23. doi: 10.1093/nar/gkt749. Epub 2013 Aug 21.
7
Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases.细菌 II 型拓扑异构酶对门控 DNA 的选择和切割的功能决定因素。
Nucleic Acids Res. 2013 Nov;41(20):9411-23. doi: 10.1093/nar/gkt696. Epub 2013 Aug 12.
8
Functional analysis of pneumococcal drug efflux pumps associates the MATE DinF transporter with quinolone susceptibility.肺炎链球菌药物外排泵的功能分析将 MATE 家族 DinF 转运蛋白与喹诺酮类药物敏感性联系起来。
Antimicrob Agents Chemother. 2013 Jan;57(1):248-53. doi: 10.1128/AAC.01298-12. Epub 2012 Oct 31.
9
Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.在肺炎链球菌的临床分离株中,编码 ABC 转运蛋白的 patA 和 patB 的过度表达与氟喹诺酮类药物耐药有关。
Antimicrob Agents Chemother. 2011 Jan;55(1):190-6. doi: 10.1128/AAC.00672-10. Epub 2010 Oct 11.
10
In front of and behind the replication fork: bacterial type IIA topoisomerases.复制叉的前后:细菌 IIA 拓扑异构酶。
Cell Mol Life Sci. 2010 Jun;67(12):2001-24. doi: 10.1007/s00018-010-0299-5. Epub 2010 Feb 18.

本文引用的文献

1
In vitro activity of fluoroquinolones against gram-positive bacteria.氟喹诺酮类药物对革兰氏阳性菌的体外活性。
Drugs. 1995;49 Suppl 2:48-57. doi: 10.2165/00003495-199500492-00009.
2
The role of new quinolones in the treatment of respiratory tract infections.新型喹诺酮类药物在呼吸道感染治疗中的作用。
Drugs. 1995;49 Suppl 2:144-51. doi: 10.2165/00003495-199500492-00024.
3
Topoisomerase IV is a target of quinolones in Escherichia coli.拓扑异构酶IV是喹诺酮类药物在大肠杆菌中的作用靶点。
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801-5. doi: 10.1073/pnas.92.25.11801.
4
Mechanism of action of quinolones against Escherichia coli DNA gyrase.喹诺酮类药物对大肠杆菌DNA旋转酶的作用机制。
Antimicrob Agents Chemother. 1993 Apr;37(4):839-45. doi: 10.1128/AAC.37.4.839.
5
A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex.DNA 回旋酶 A 蛋白中的单个点突变极大地降低了氟喹诺酮类药物与回旋酶-DNA 复合物的结合。
Antimicrob Agents Chemother. 1993 Jan;37(1):126-7. doi: 10.1128/AAC.37.1.126.
6
Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.大肠杆菌拓扑异构酶IV。纯化、特性、亚基结构及亚基相互作用
J Biol Chem. 1993 Nov 15;268(32):24481-90.
7
New quinolones and gram-positive bacteria.新型喹诺酮类药物与革兰氏阳性菌
Antimicrob Agents Chemother. 1994 Feb;38(2):163-9. doi: 10.1128/AAC.38.2.163.
8
Isolation, characterization, and nucleotide sequence of IS1202, an insertion sequence of Streptococcus pneumoniae.肺炎链球菌插入序列IS1202的分离、特性鉴定及核苷酸序列分析
J Bacteriol. 1994 Jul;176(14):4437-43. doi: 10.1128/jb.176.14.4437-4443.1994.
9
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构:氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
10
Nucleotide sequence of the recF gene cluster from Staphylococcus aureus and complementation analysis in Bacillus subtilis recF mutants.金黄色葡萄球菌recF基因簇的核苷酸序列及在枯草芽孢杆菌recF突变体中的互补分析。
Mol Gen Genet. 1995 Mar 20;246(6):680-6. doi: 10.1007/BF00290713.

肺炎链球菌编码DNA拓扑异构酶IV的parC和parE基因的克隆与特性分析:在氟喹诺酮耐药性中的作用

Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

作者信息

Pan X S, Fisher L M

机构信息

Molecular Genetics Group, Department of Cellular and Molecular Sciences, St. George's Hospital Medical School, University of London, United Kingdom.

出版信息

J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.

DOI:10.1128/jb.178.14.4060-4069.1996
PMID:8763932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC178161/
Abstract

DNA topoisomerase IV mediates chromosome segregation and is a potential target for antibacterial agents including new antipneumococcal fluoroquinolones. We have used hybridization to a Staphylococcus aureus gyrB probe in concert with chromosome walking to isolate the Streptococcus pneumoniae parE-parC locus, lying downstream of a putative new insertion sequence and encoding 647-residue ParE and 823-residue ParC subunits of DNA topoisomerase IV. These proteins exhibited greatest homology respectively to the GrlB (ParE) and GrlA (ParC) subunits of S. aureus DNA topoisomerase IV. When combined, whole-cell extracts of Escherichia coli strains expressing S. pneumoniae ParC or ParE proteins reconstituted a salt-insensitive ATP-dependent decatenase activity characteristic of DNA topoisomerase IV. A second gyrB homolog isolated from S. pneumoniae encoded a 648-residue protein which we identified as GyrB through its close homology both to counterparts in S. aureus and Bacillus subtilis and to the product of the S. pneumoniae nov-1 gene that confers novobiocin resistance. gyrB was not closely linked to gyrA. To examine the role of DNA topoisomerase IV in fluoroquinolone action and resistance in S. pneumoniae, we isolated mutant strains stepwise selected for resistance to increasing concentrations of ciprofloxacin. We analysed four low-level resistant mutants and showed that Ser-79 of ParC, equivalent to resistance hotspots Ser-80 of GrlA and Ser-84 of GyrA in S. aureus, was in each case substituted with Tyr. These results suggest that DNA topoisomerase IV is an important target for fluoroquinolones in S. pneumoniae and establish this organism as a useful gram-positive system for resistance studies.

摘要

DNA拓扑异构酶IV介导染色体分离,是包括新型抗肺炎球菌氟喹诺酮类药物在内的抗菌剂的潜在靶点。我们利用与金黄色葡萄球菌gyrB探针的杂交技术,并结合染色体步移法,分离出肺炎链球菌parE-parC基因座,该基因座位于一个假定的新插入序列下游,编码DNA拓扑异构酶IV的647个氨基酸残基的ParE亚基和823个氨基酸残基的ParC亚基。这些蛋白质分别与金黄色葡萄球菌DNA拓扑异构酶IV的GrlB(ParE)和GrlA(ParC)亚基具有最高的同源性。当将表达肺炎链球菌ParC或ParE蛋白的大肠杆菌菌株的全细胞提取物混合时,可重建DNA拓扑异构酶IV特有的对盐不敏感的ATP依赖性解连环酶活性。从肺炎链球菌中分离出的第二个gyrB同源物编码一个648个氨基酸残基的蛋白质,通过其与金黄色葡萄球菌和枯草芽孢杆菌中的对应物以及赋予新生霉素抗性的肺炎链球菌nov-1基因产物的密切同源性,我们将其鉴定为GyrB。gyrB与gyrA没有紧密连锁。为了研究DNA拓扑异构酶IV在肺炎链球菌氟喹诺酮作用和耐药性中的作用,我们逐步分离出对环丙沙星浓度增加具有抗性的突变菌株。我们分析了四个低水平抗性突变体,结果表明ParC的79位丝氨酸,相当于金黄色葡萄球菌中GrlA的80位丝氨酸和GyrA的84位丝氨酸耐药热点,在每种情况下都被酪氨酸取代。这些结果表明,DNA拓扑异构酶IV是肺炎链球菌中氟喹诺酮类药物的重要靶点,并将该生物体确立为耐药性研究的有用革兰氏阳性系统。